A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Dose Concentrations of CC-93538 in Healthy Adult Subjects
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Cendakimab (Primary)
- Indications Atopic dermatitis; Eosinophilic oesophagitis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 24 Sep 2021 Status changed from recruiting to completed.
- 17 Sep 2021 Results presented at the 2021 American College of Clinical Pharmacology Annual Meeting
- 16 Feb 2021 Planned End Date changed from 23 Nov 2020 to 25 May 2021.